Literature DB >> 32581248

A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels.

Arian Lundberg1,2, Linda S Lindström3, Joel S Parker4, Elinor Löverli1, Charles M Perou4,5, Jonas Bergh1,6, Nicholas P Tobin7.   

Abstract

Pan-cancer genomic analyses based on the magnitude of pathway activity are currently lacking. Focusing on the cell cycle, we examined the DNA mutations and chromosome arm-level aneuploidy within tumours with low, intermediate and high cell-cycle activity in 9515 pan-cancer patients with 32 different tumour types. Boxplots showed that cell-cycle activity varied broadly across and within all cancers. TP53 and PIK3CA mutations were common in all cell cycle score (CCS) tertiles but with increasing frequency as cell-cycle activity levels increased (P < 0.001). Mutations in BRAF and gains in 16p were less frequent in CCS High tumours (P < 0.001). In Kaplan-Meier analysis, patients whose tumours were CCS Low had a longer Progression Free Interval (PFI) relative to Intermediate or High (P < 0.001) and this significance remained in multivariable analysis (CCS Intermediate: HR = 1.37; 95% CI 1.17-1.60, CCS High: 1.54; 1.29-1.84, CCS Low = Ref). These results demonstrate that whilst similar DNA alterations can be found at all cell-cycle activity levels, some notable exceptions exist. Moreover, independent prognostic information can be derived on a pan-cancer level from a simple measure of cell-cycle activity.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32581248     DOI: 10.1038/s41388-020-1367-4

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

1.  A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.

Authors:  Xiangkun Wu; Daojun Lv; Chao Cai; Zhijian Zhao; Ming Wang; Wenzhe Chen; Yongda Liu
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

2.  Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models.

Authors:  Delphine Lissa; Nobuyuki Takahashi; Parth Desai; Irena Manukyan; Christopher W Schultz; Vinodh Rajapakse; Moises J Velez; Deborah Mulford; Nitin Roper; Samantha Nichols; Rasa Vilimas; Linda Sciuto; Yuanbin Chen; Udayan Guha; Arun Rajan; Devon Atkinson; Rajaa El Meskini; Zoe Weaver Ohler; Anish Thomas
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

3.  Reclassifying tumour cell cycle activity in terms of its tissue of origin.

Authors:  Arian Lundberg; Joan Jong Jing Yi; Linda S Lindström; Nicholas P Tobin
Journal:  NPJ Precis Oncol       Date:  2022-08-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.